Expert buy, hold and sell recommendations from our team of analysts.
The February reporting season kicked off in the week ending Friday 7 February 2025, with FNArena recording nine upgrades and 14 downgrades for ASX-listed companies by brokers monitored daily.
Michael Gable does the BUY or SELL charts on the market indexes, CBA, RIO, LYNAS, AD8, AND MORE.
Anyone wanting to invest with total confidence wouldn’t be satisfied with news out of the US overnight.
This tariff-fuelled market volatility presents an opportunity for long-term investors. I’d use any period of extended volatility to buy into market weakness, capitalise on lower asset prices, and add to portfolio exposures. Here are two ways I’d play this.
In our “HOT” stock article today, Michael Gable, MD of Fairmont Equities, says that Silex Systems is setting itself up for another decent move higher.
Should I consider the ‘short’ position in a stock before deciding to buy? Should I vote in favour of a proposal to restructure a company that is currently suspended from the ASX? Do the brokers see further upside for Aristocrat Leisure? When does CBA announce its first half profit?
Peter Switzer & Adam Dawes answers your questions on MQG, PNV, REA & more
Playing Donald Trump’s tariffs involves calculating the risk of just how serious a trade war might become. Here are a few ways to play the tariff world of 2025 and beyond.
Led by a buoyant Wall Street, the Australian share market hit a record high at the end of January. Our model portfolios followed suit and recorded solid gains for the month. In this article, we look at how they have performed so far in 2025.
In our “HOT STOCK” column today, Raymond Chan, Head of Asian Desk at Morgan’s explains why he regards ResMed (RMD) as an ADD to an investor’s portfolio.
You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.